NewsRoom Articles - Page 20 of 1455

ThursdayJun 25, 2026 9:00 am

Zacks Initiates Coverage of Versus Systems Inc. (NASDAQ: VS) as Company Advances Gamification and Audience Engagement Strategy

Zacks Investment Research noted progress in the company’s gamification business and potential growth catalysts despite broader industry challenges. A key factor was the company’s unique technology, plus improved first-quarter 2026 financial results, including significantly reduced operating losses and positive operating cash flow. Versus Systems offers a unique technology platform combining interactive gaming, real-world rewards, and advertising experiences designed to increase customer engagement and loyalty. Versus’ Winfinite and Filter Fan Cam products provide opportunities across digital marketing, sports, entertainment, and live-event environments. The company’s relationship with ASPIS and the potential extension of its technology licensing agreement may provide future recurring revenue…

WednesdayJun 24, 2026 11:15 am

VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC-ADC Platform as It Expands Next-Generation Cancer Therapy Pipeline

VERAXA Biotech has reported new in vitro proof-of-concept data supporting its BiTAC-ADC technology, demonstrating selective activity against cancer cells while sparing healthy cells in early testing. The company is presenting its BiTAC-ADC and BiTAC-TCE platforms for potential strategic collaborations at the BIO International Convention 2026. VERAXA’s proprietary BiTAC approach is designed to improve the precision of antibody-based cancer therapies by activating therapeutic effects only in targeted tumor cells. The company maintains a diversified oncology pipeline of antibody-based formats including antibody-drug conjugates (“ADCs”), T-cell engagers (“TCEs”), and other antibody-based formats. VERAXA recently began trading on the NASDAQ Capital Market under the…

WednesdayJun 24, 2026 10:30 am

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF): Cancer Nanomedicine Enters a New Generation

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising. Cancer nanomedicine is emerging from an early period of skepticism, with more than 20 approved formulations now improving therapeutic index and patient quality of life during treatment Onco-Innovations' lead drug candidate, ONC010, pairs a small-molecule PNKP inhibitor with a polymer nanodelivery system designed to extend circulation, increase drug retention in tumor, and improve tolerability Recent manufacturing updates, including kilogram-scale precursor production and a proposed Nanosoft Polymers collaboration, point to a sharpening focus on scalability, reproducibility, and regulatory readiness ahead of first-in-human studies For decades,…

WednesdayJun 24, 2026 9:45 am

Beeline Holdings Inc. (NASDAQ: BLNE) Joins Russell Microcap Index as Digital Mortgage Platform Expands AI and Equity Strategy

Beeline’s AI-enabled underwriting and customer acquisition tools are designed to reduce friction in mortgage approvals, particularly for gig-economy borrowers. Shares of Beeline Holdings, Inc. are set to join the Russell Microcap Index effective June 29, increasing visibility among institutional investors. The company’s first-quarter 2026 revenue more than doubled year over year to $2.7 million, while loan originations rose to $85.6 million. Management is targeting younger real estate investors alongside older homeowners seeking access to home equity without refinancing. The company continues investing in automation and adjacent software capabilities as it pursues a broader housing finance technology strategy. Beeline Holdings (NASDAQ:…

WednesdayJun 24, 2026 9:00 am

Greenland Mines Ltd. (NASDAQ: GRML) Is ‘One to Watch’

Greenland Mines’ flagship Skaergaard Project hosts an NI 43-101 Mineral Resource estimate containing 11.4 million ounces PdEq in the Indicated category and 14.1 million ounces PdEq in the Inferred category. The pending acquisition of the Sarfartoq Project would add an advanced rare earth asset with a historical resource estimate, extensive drilling history and exposure to magnet rare earth elements including neodymium and praseodymium. The company’s relationship with Neo Performance Materials includes an offtake arrangement covering up to 60% of future Sarfartoq production, subject to completion of the acquisition and future project development. Greenland Mines is pursuing a North Atlantic critical…

TuesdayJun 23, 2026 11:15 am

ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Announces Another Infrastructure Milestone Amid Advancements Toward Commissioning of Montauban Project Site

Disseminated on behalf of ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) and may include paid advertising. ESGold Corp., a development-stage company committed to the acquisition, exploration, and development of high-quality mineral properties worldwide, recently received the delivery of a propane-fired tilting furnace at its Montauban Project to support on-site melting and casting of gold and silver into doré bars The furnace will form part of the company’s planned circuit for recovering precious metals from permitted tailings material and is a crucial milestone as the company moves to operationalize the facility ESGold has received – and continues to receive – infrastructure and…

TuesdayJun 23, 2026 10:30 am

The $410 Billion Drug Delivery Revolution: Why Drug Delivery May Be the Next Major Frontier in Oncology Innovation

The rapidly expanding nanomedicine and advanced drug-delivery market is attracting growing attention as pharmaceutical companies seek ways to improve therapeutic performance without relying solely on costly new drug discovery programs. By addressing challenges such as poor bioavailability, inconsistent pharmacokinetics and limited tumor penetration, nanotechnology-based delivery systems may unlock additional value from existing oncology drugs. Oncotelic Therapeutics' Deciparticle(TM) platform and Sapu003 program illustrate how innovative drug delivery approaches could help reshape the future of cancer treatment. The search for new cancer therapies has traditionally focused on discovering entirely new drug candidates. While this approach has produced important breakthroughs, it is also…

TuesdayJun 23, 2026 9:45 am

Greenland Energy Company (NASDAQ: GLND) Advances Jameson Project as Greenland Pursues Greater Economic Self-Sufficiency

GLND is advancing exploration at the Jameson Project, one of Greenland's most prospective yet historically underexplored resource regions The company is focused on unlocking economic opportunities that could support job creation, infrastructure development, and long-term revenue generation These developments align with a broader vision: empowering Greenland's path toward greater economic independence through responsible resource development Greenland Energy (NASDAQ: GLND) is positioning itself at the intersection of one of the Arctic’s most compelling economic opportunities. Through the company’s Jameson Project in East Greenland, it is pursuing resource exploration in an area that has long attracted geological interest but has seen only…

TuesdayJun 23, 2026 9:00 am

7th Clinical Trial Agreements Summit to Address Evolving Contracting Challenges in Clinical Research

Date: August 27, 2026 Venue: Sonesta Philadelphia Rittenhouse Hotel, Philadelphia, PA Professionals and executives from clinical, legal, regulatory, and operational sectors are invited to attend the 7th Clinical Trial Agreements Summit, to be held on Aug. 27-28, 2026, at the Sonesta Philadelphia Rittenhouse Hotel in Philadelphia, Pennsylvania. The event is hosted by Dynamic Global Events (“DGE”), a world leader in curating b2b events for life science companies. The summit aims to guide stakeholders in navigating the complex landscape of clinical trial agreements (“CTAs”), as they adapt to new regulations, technologies, and best practices. Why attend? Industry experts will explore practical…

MondayJun 22, 2026 11:15 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Targets a $393 Billion Heart Disease Problem with Epigenetics and AI

For cardiovascular conditions, annual health care costs are forecasted to increase from $393 billion in 2020 to $1.4 trillion by 2050, almost quadrupling in size. What makes Cardio Diagnostics' approach distinct, and what gives the company a defensible clinical position, is its ability to detect coronary heart disease earlier and with high sensitivity. The company's recent commercial and regulatory milestones give additional shape to the investment thesis. Heart disease has held the grim distinction of being the leading cause of death in the United States for decades, and despite advances in medicine, the problem is getting worse, not better. According…

Financial news and publishing for public and private companies

Contact us: 512.354.7000